Effect of everolimus introduction on cardiac allograft vasculopathy-results of a randomized, multicenter trial

Transplantation

Volumn 92, Issue 2, 2011, Pages 235-243

  Arora, Satish ^a   Ueland, Thor ^a   Wennerblom, Bertil ^b   Sigurdadottir, Vilborg ^b   Eiskjær, Hans ^c   Bøtker, Hans E ^c   Ekmehag, Bjorn ^d   Jansson, Kjell ^e   Mortensen, Svend Aage ^f   Saunamaki, Kari ^f   Simonsen, Svein ^a   Gude, Einar ^a   Bendz, Bjørn ^a   Solbu, Dag ^g   Aukrust, Pål ^a,h   Gullestad, Lars ^a,h  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^c AARHUS UNIVERSITY HOSPITAL   (Denmark)

^d LUND UNIVERSITY HOSPITAL   (Sweden)

^e LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^f Rigshospitalet   (Denmark)

^g Novartis Pharma   (Norway)

^h UNIVERSITY OF OSLO   (Norway)

Author keywords

Cardiac allograft vasculopathy; Everolimus; Intravascular ultrasound

Indexed keywords

AZATHIOPRINE; C REACTIVE PROTEIN; CALCINEURIN INHIBITOR; EVEROLIMUS; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS; VASCULAR CELL ADHESION MOLECULE 1; VON WILLEBRAND FACTOR;

ACCURACY; ADULT; ARTERIAL WALL THICKNESS; ARTICLE; ATHEROMA; CARDIAC ALLOGRAFT VASCULOPATHY; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; GRAFT RECIPIENT; HEART TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTRAVASCULAR ULTRASOUND; LOW DRUG DOSE; LUNG TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; UNSPECIFIED SIDE EFFECT;

AGED; AZATHIOPRINE; C-REACTIVE PROTEIN; CALCINEURIN; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; RISK FACTORS; SCANDINAVIA; SIROLIMUS; ULTRASONOGRAPHY, INTERVENTIONAL; VASCULAR CELL ADHESION MOLECULE-1; VASCULAR DISEASES; VON WILLEBRAND FACTOR;

EID: 79960305705     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e31822057f1     Document Type: Article

References (27)

1. Taylor DO, Stehlik J, Edwards LB, et al. Registry of the International Society for Heart and Lung Transplantation: Twenty-sixth official adult heart transplant report- 2009. J Heart Lung Transplant 2009; 28: 1007.
2. Eisen H, Kobashigawa J, Starling RC, et al. Improving outcomes in heart transplantation: The potential of proliferation signal inhibitors. Transplant Proc 2005; 37: 4S.
3. Dambrin C, Klupp J, Birsan T, et al. Sirolimus (rapamycin) mono-therapy prevents graft vascular disease in nonhuman primate recipi-ents oforthotopic aortic allografts. Circulation 2003; 107: 2369.
4. Eisen HJ, Tuzcu EM, Dorent R, et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. NEngl J Med 2003; 349: 847.
5. Johnson DE, Gao SZ, Schroeder JS, et al. The spectrum of coronary artery pathologic findings in human cardiac allografts. JHeart Transplant 1989; 8:349.
6. Valantine HA. Cardiac allograft vasculopathy: Central role ofendothe-lial injury leading to transplant "atheroma." Transplantation 2003; 76: 891.
7. Gullestad L, Iversen M, Mortensen SA, et al. Everolimus with reduced calcineurin inhibitor in thoracic transplant recipients with renal dys-function: A multicenter, randomized trial. Transplantation 2010; 89: 864.
8. Mintz GS, Nissen SE, Anderson WD, et al. American College ofcardiology clinical expert consensus document on standards for acquisition, measure-ment and reporting ofintravascular ultrasound studies (IVUS). A report of the American College of Cardiology Task Force on Clinical Expert Con-sensus Documents. JAm Coll Cardiol 2001; 37: 1478.
9. Mancini D, Pinney S, Burkhoff D, et al. Use of rapamycin slows progres-sion ofcardiac transplantation vasculopathy. Circulation 2003; 108:48.
10. Raichlin E,Bae JH, Khalpey Z, et al. Conversiontosirolimusasprimary immunosuppression attenuates the progression of allograft vasculopa-thyafter cardiac transplantation. Circulation 2007; 116: 2726.
11. Day JD, Rayburn BK, Gaudin PB, et al. Cardiac allograft vasculopathy: The central pathogenetic role ofischemia-induced endothelial cell in-jury. J Heart Lung Transplant 1995; 14: S142.
12. Segovia J, Gomez-Bueno M, Alonso-Pulpon L. Treatment of allograft vasculopathy in heart transplantation. Expert Opin Pharmacother 2006; 7: 2369.
13. Wenke K, Meiser B, Thiery J, et al. Simvastatin initiated earlyafter heart transplantation: 8-year prospective experience. Circulation 2003; 107:93.
14. Hiatt WR, Nissen SE. New drug application21-628, Certican (everoli-mus), for the proposed indication of prophylaxis of rejection in heart transplantation: Report from the Cardiovascular and Renal Drugs Ad-visory Committee, US Food and Drug Administration, November 16, 2005, Rockville, MD. Circulation 2006; 113: e394.
15. Rothenburger M, Zuckermann A, Bara C, et al. Recommendations for the use of everolimus (Certican) in heart transplantation: Results from the second German-Austrian Certican Consensus Conference. JHeart Lung Transplant 2007; 26: 305.
16. Arora S, Gunther A, Wennerblom B, et al. Systemic markers ofinflamma-tion are associated with cardiac allograft vasculopathy and an increased intimalinflammatorycomponent. Am J Transplant 2010; 10:1428.
17. Taylor AL, Watson CJ, Bradley JA. Immunosuppressive agents in solid organ transplantation: Mechanisms of action and therapeutic efficacy. Crit Rev Oncol Hematol 2005; 56: 23.
18. Eisen HJ, Kobashigawa J, Keogh A, et al. Three-year results ofarandom-ized, double-blind, controlled trial of mycophenolate mofetil versus aza-thioprine in cardiac transplant recipients. J Heart Lung Transplant 2005; 24:517.
19. Kobashigawa JA, Meiser BM. Review of major clinical trials with my-cophenolate mofetil in cardiac transplantation. Transplantation 2005; 80: S235.
20. Dandel M, Lehmkuhl HB, Knosalla C, et al. Impact ofdifferent long-term maintenance immunosuppressive therapy strategies on patients' outcome after heart transplantation. Transpl Immunol 2010; 23: 93.
21. Keogh A. Long-term benefits ofmycophenolate mofetil after heart transplantation. Transplantation 2005; 79: S45.
22. Reichart B, Meiser B, Vigano M, et al. European Multicenter Tacrolimus (FK506) Heart Pilot Study: One-year results\-European Tacrolimus Mul-ticenter Heart Study Group. JHeart Lung Transplant 1998; 17: 775.
23. Kobashigawa JA, Tobis JM, Starling RC, et al. Multicenter intravascular ultrasound validation study among heart transplant recipients: Out-comes after five years. JAm Coll Cardiol 2005; 45: 1532.
24. Manito N, Delgado JF, Crespo-Leiro MG, et al. Clinical recommenda-tions for the use of everolimus in heart transplantation. Transplant Rev (Orlando) 2010; 24: 129.
25. Mehra MR, Ventura HO, Stapleton DD, et al. Presence of severe intimal thickening by intravascular ultrasonography predicts cardiac events in car-diacallograftvasculopathy. JHeart Lung Transplant 1995; 14:632.
26. Bollerslev J, Ueland T, Jorgensen AP, et al. Positive effects of a physio-logical dose of GH on markers ofatherogenesis: A placebo-controlled study in patients with adult-onset GH deficiency. Eur J Endocrinol 2006; 154:537.
27. Arora S, Gullestad L, Wergeland R, et al. Probrain natriuretic peptide and C-reactive protein as markers ofacute rejection, allograft vascu-lopathy, and mortality in heart transplantation. Transplantation 2007; 83: 1308.